Prostate cancer
Conditions
Brief summary
The difference in the AUC (area under curve) of dexamethasone serum concentration before, and after steady-state, of two different antiandrogens (enzalutamide or apalutamide).
Detailed description
To evaluate the AUC following administration of a doubled dose of dexamethasone during ongoing treatment with antiandrogens (enzalutamide or apalutamide)., To assess whether doubling the corticosteroid dose can compensate for any reduction of the AUC by antiandrogen therapy (enzalutamide or apalutamide)., To evaluate possible adverse events of giving a single dose dexamethasone at three separate occasions.
Interventions
DRUGDexacur 4 mg/ml injektions-/infusionsvätska
DRUGlösning
Sponsors
Region Vaesterbotten
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The difference in the AUC (area under curve) of dexamethasone serum concentration before, and after steady-state, of two different antiandrogens (enzalutamide or apalutamide). | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate the AUC following administration of a doubled dose of dexamethasone during ongoing treatment with antiandrogens (enzalutamide or apalutamide)., To assess whether doubling the corticosteroid dose can compensate for any reduction of the AUC by antiandrogen therapy (enzalutamide or apalutamide)., To evaluate possible adverse events of giving a single dose dexamethasone at three separate occasions. | — |
Outcome results
None listed